The NHS in 2026 is facing a familiar but intensifying oncology challenge. Our data at HSJ Information shows rising incidence, workforce strain, diagnostic bottlenecks and stark inequalities in outcomes.
Yet this is also a moment of opportunity for pharma.
The recently published NHS Cancer Plan sets out a reform agenda centred on earlier diagnosis, smarter use of data, faster access to innovation and system-wide collaboration through Cancer Alliances and Integrated Care Boards (ICBs).
Check out the rest of the feature here
